This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Health technology
The use of two combination treatments for patients with inoperable non-small-cell lung cancer (NSCLC). The treatments were paclitaxel plus carboplatin (PC) and paclitaxel plus gemcitabine (PG). In the PC group, paclitaxel (175 mg/m2) was given as a 3-hour intravenous infusion, followed by carboplatin intravenously (AUC = 7) for 1 hour on day 1 every 3 weeks. In the PG group, paclitaxel (175 mg/m2) was given intravenously on day 1, while gemcitabine (1,000 mg/m2) was administered intravenously for 30 minutes on days 1 and 8 every 3 weeks. The treatment regimens were modified when required.
Type of intervention
Treatment.
Economic study type
Cost-effectiveness analysis.
Study population
The study population comprised patients with the following characteristics: a cytological or histological diagnosis of locally advanced (stage IIIb, including those with malignant pleural effusions) or metastatic (stage IV) NSCLC; age between 18 to 80 years; no prior chemotherapy, radiotherapy or immunotherapy; a performance status of 0 to 2 on the World Health Organization (WHO) scale; bidimensionally measurable disease; adequate bone marrow reserve with a blood cell count of at least 4,000/mm3, a platelet count of at least 100,000/mm3, and a haemoglobin level of at least 10 g/dL; and female patients with appropriate contraception.
Patients were excluded if they presented signs or symptoms of brain metastases, a recent myocardial infarction more than 3 months before the date of diagnosis, unstable angina, inadequate liver function (bilirubin greater than 1.5 times and ALT/AST greater than 3 times the upper normal limit), or inadequate renal function with creatinine greater than 2.0 mg/dL. Patients with a second primary malignancy, except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin, were also excluded.
